我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

小剂量替罗非班治疗高原非ST段抬高型急性冠脉综合征的临床观察(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第5期
页码:
620-622
栏目:
临床研究
出版日期:
2011-10-25

文章信息/Info

Title:
Clinical observation of low-dose tirofiban in patients with non-ST segment elevation acute coronary syndrome at high altitude
作者:
吴久健1; 姜大春2; 尹 刚1; 虞慎也1; 吴 鹏1; 石国芹1
解放军第37医院:1.药械科，2.心内科，四川 雅安 625000
Author(s):
WU Jiu-jian1;  JIANG Da-chun2;  YIN Gang1;  YU Shen-ye1;  WU Peng1;  SHI Guo-qin1
1.Department of Drug and Equipment, 2.Department of Cardiology, PLA 37 Hospital, Ya’an 625000, Sichuan, China
关键词:
高原; 替罗非班; 急性冠脉综合征
Keywords:
high altitude;  tirofiban;  acute coronary syndrome
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:观察小剂量替罗非班治疗高原非ST段抬高型急性冠脉综合征(NSTE-ACS)患者的疗效及安全性。方法： 将75例NSTE-ACS患者随机分为对照组(n=37)和观察组(n=38)。两组均常规使用阿司匹林、氯吡格雷、低分子肝素等药物治疗，观察组加用小剂量替罗非班［负荷量0.3 μg/（kg·min）×30 min，维持量0.05 μg/（kg·min）×72 h］微量泵静脉泵入。检测治疗前后血小板计数和血小板聚集率；观察30 d内心血管事件和出血事件的发生率。结果： 对照组30 d内心血管事件的发生率为22%，观察组为5%，两组间有显著差异(P<0.05)；对照组30 d内出血事件的发生率为5%，观察组为8%，两组间无显著差异；对照组血小板聚集率治疗前后无显著变化，观察组治疗后血小板聚集率显著降低(P<0.05)。两组患者中均未观察到血小板减少的发生。结论： 小剂量替罗非班联合阿司匹林、氯吡格雷和低分子肝素治疗高原NSTE-ACS是安全和有效的。
Abstract:
AIM:To observe the effectiveness and safety of low-dose tirofiban in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) at high altitude. METHODS: A total of 75 patients with NSTE-ACS were randomized into control group (n=37) and tirofiban group (n=38). Patients in both groups were treated with aspirin, clopidogrel and low molecular weight heparin therapy. Patients in tirofiban group were treated with tirofiban ［load dose 0.3 μg/(kg·min)×30 min, maintaining dose 0.05 μg/(kg·min)×72 h］. Platelet count and platelet adhesion rate were measured before and after tirofiban treatment. Incidence of cardiovascular events and hemorrhage within 30 days were recorded. RESULTS: Incidence of cardiovascular events within 30 days in control group was significantly higher than in tirofiban group (22% vs. 5%, P<0.05). Incidence of hemorrhage was similar between groups (5% vs. 8%, P>0.05). Platelet adhesion rate was significantly reduced in tirofiban group but no similar change was seen in control group. No reduction of platelet count was observed in either group. CONCLUSION: Treatment with low-dose tirofiban is an effective and safe strategy for patients with NSTE-ACS at high altitude.

参考文献/References

[1]Rohit A,Fasi R.Antiplatelet intervention in acute coronary syndrome[J].Am J Ther,2009,16(5):e29-e40.

[2]Hamm CW.Current practice and limitations of dual antiplatelet therapy in acute coronary syndrome[J].Eur Heart J Suppl,2009,11(suppl):G 4-G8.

[3]McClellan KJ,Goa KL. Tirofiban. A review of its use in acute coronary syndromes[J].Drugs,1998,56(6):1067-1080.

[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4)：295-304.

[5]张庆成，盂腾涛，司本辉，等.高原缺氧环境对青年战士血小板活化的影响[J].环境与健康杂志,2000,17(3)：142-144.

[6]肖青林,郜中平,陈广浩，等.高原低氧环境对人血小板功能的影响[J].武警医学,2005,16(10):758-759.

[7]Libby P.Current concepts of the pathogenesis of the acute coronary syndromes[J].Circulation,2001,104(3):365-372.

[8]Becker RC, Gibson CM,Jennings LK,et al. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions [J].Am J Cardiol,2010,106(8):S2-S3.

[9]Spinler SA.Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention:balancing efficacy and bleeding risk[J].Am J Health Syst Pharm,2010,67(15 Suppl 7):S7-S17.

[10]Valgimigli M.Balancing safety and efficacy:recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome[J]Eur Heart J Suppl,2010,12(suppl):D14-D23.

备注/Memo

备注/Memo:
收稿日期：2011-02-10.基金项目：成都军区医学科研计划课题资助(MB09016) 通讯作者：姜大春，副主任医师，主要从事冠心病的临床研究Email:jiangdc@sohu.com 作者简介：吴久健，副主任医师Email:dr_wjj@yahoo.cn
更新日期/Last Update: 2011-11-03